Terns Pharmaceuticals
TERN
Market cap $626M

7.41 USD

-0.09

1.20%

At close Oct 18, 4:00 PM EDT

After hours

7.59

+0.18

2.43%

1 day

-1.20%

5 days

-3.39%

1 month

-27.42%

3 months

-14.73%

6 months

61.44%

Year to date

14.35%

1 year

28.87%

5 years

-59.71%

About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Employees: 66

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

359% more call options, than puts

Call options by funds: $3.72M | Put options by funds: $809K

200% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]

88% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 24

60% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 25

14% more funds holding

Funds holding: 111 [Q1] → 126 (+15) [Q2]

7% more capital invested

Capital invested by funds: $418M [Q1] → $447M (+$28.9M) [Q2]

2.89% more ownership

Funds ownership: 98.51% [Q1] → 101.4% (+2.89%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

102%

upside

Avg. target

$20

170%

upside

High target

$26

251%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

BMO Capital Etzer Darout 67% 1-year accuracy 20 / 30 met price target	251%upside $26	Outperform Reiterated	16 Sept 2024
JMP Securities Silvan Tuerkcan 43% 1-year accuracy 21 / 49 met price target	170%upside $20	Market Outperform Maintained	10 Sept 2024
JMP Securities Silvan Tuerkcan 43% 1-year accuracy 21 / 49 met price target	102%upside $15	Market Outperform Reiterated	3 Sept 2024
BMO Capital Etzer Darout 67% 1-year accuracy 20 / 30 met price target	156%upside $19	Outperform Reiterated	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected in December 2024, offering another investment opportunity.

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

The Motley Fool

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival.

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

The Motley Fool

Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.

Viking Therapeutics isn't the only weight loss biotech out there. Terns Pharmaceuticals just published some good phase 1 clinical trial data.

Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.

The Motley Fool

Should You Invest in This Under-the-Radar Weight Loss Stock?

Terns Pharmaceuticals' early-stage weight loss asset just reported positive clinical trial results. Even though it's showing some promise, Terns remains a risky bet.

Should You Invest in This Under-the-Radar Weight Loss Stock?

The Motley Fool

1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More

Terns Pharmaceuticals just reported some strong data from a phase 1 clinical trial. The data suggest that it might be able to make a highly tolerable weight loss drug.

1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

The 'Undercovered' Dozen series highlights 12 undercovered stocks, providing investment ideas and sparking community discussion on their potential. Zach Bristow argues that Sylvamo Corporation offers a compelling risk/reward opportunity with reasonable valuations, shareholder-oriented management, and potential valuations up to $200/share. NuScale Power Corporation faces skepticism, according to George Theodosi, due to overhype and lack of US SMR projects, despite global interest in nuclear energy.

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

FOSTER CITY, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the closing of its previously announced underwritten public offering of 14,064,048 shares of its common stock, including 2,145,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock, at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are approximately $172.7 million. All of the securities were offered by Terns.

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Terns Announces Pricing of Upsized $150.15 Million Public Offering

FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be approximately $150.15 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 12, 2024, subject to customary closing conditions. All of the securities are being offered by Terns.

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Zacks Investment Research

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

See News Rankings

Charts implemented using Lightweight Charts™